Growth Metrics

Novartis Ag (NVS) Enterprise Value (QoQ) (2009 - 2025)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -635.07%
Sep 30, 2025 106.32%
Jun 30, 2025 -222,533.33%
Mar 31, 2025 100.14%
Dec 31, 2024 -800.00%
Sep 30, 2024 96.96%
Dec 31, 2023 -2,127.48%
Sep 30, 2023 94.60%
Jun 30, 2023 -1,191,700.00%
Mar 31, 2023 100.01%
Dec 31, 2022 -188,390.00%
Sep 30, 2022 99.72%
Jun 30, 2022 -4,754.79%
Mar 31, 2022 99.74%
Dec 31, 2021 -18,152.56%
Sep 30, 2021 103.10%
Jun 30, 2021 -83,750.00%
Mar 31, 2021 99.95%
Dec 31, 2020 -192,533.33%
Sep 30, 2020 99.90%
Jun 30, 2020 -7,386.08%
Mar 31, 2020 99.29%
Dec 31, 2019 -15,094.59%
Sep 30, 2019 100.56%
Jun 30, 2019 -3,033.73%
Mar 31, 2019 97.24%
Dec 31, 2018 -18,964.20%
Sep 30, 2018 100.92%
Jun 30, 2018 -292,566.67%
Mar 31, 2018 100.03%
Dec 31, 2017 -4,866.33%
Sep 30, 2017 102.70%
Jun 30, 2017 -6,732.43%
Mar 31, 2017 101.53%
Dec 31, 2016 -4,664.78%
Sep 30, 2016 -99.83%
Jun 30, 2016 -51.04%
Mar 31, 2016 4,095.01%
Dec 31, 2015 96.36%
Sep 30, 2015 -6,599,550,000,100.00%
Jun 30, 2015 -97.06%
Mar 31, 2015 100.00%
Dec 31, 2014 -480,986,486,586.49%
Sep 30, 2014 146.67%
Jun 30, 2014 11.11%
Mar 31, 2014 -76.92%
Dec 31, 2013 -11.36%
Sep 30, 2013 -2.22%
Jun 30, 2013 13.45%
Sep 30, 2012 10.81%
Jun 30, 2012 404.55%
Mar 31, 2012 -77.08%
Dec 31, 2011 -1.03%
Sep 30, 2011 340.91%
Jun 30, 2011 -56.86%
Mar 31, 2011 -70.86%
Dec 31, 2010 121.52%
Sep 30, 2010 295.00%
Jun 30, 2010 33.33%
Mar 31, 2010 100.00%
Dec 31, 2009 -8,038,888,838.89%
Sep 30, 2009 300.00%
Jun 30, 2009 -30.77%